Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Chemoradiation with Interferon Alfa in Locally Advanced Pancreatic Cancer
NCT00262951Phase 2Terminated
- Sponsor
- Masonic Cancer Center
- Start
- Jan 2005
- Primary completion
- Apr 2011
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of interferon alfa in pancreatic adenocarcinoma (PDAC), sponsored by Masonic Cancer Center. Primary endpoint: Number of Patients in Whom Tumor Was Resectable. Started Jan 2005; status: terminated.
02
Drugs
interferon alfa
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00262951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00262951.